Neeraj Agarwal: American Cancer Society Updates Its Approach to Prostate Cancer Screening
Neeraj Agarwal/ X

Neeraj Agarwal: American Cancer Society Updates Its Approach to Prostate Cancer Screening

Neeraj Agarwal, Co-Director of Prostate Cancer Program at Dana-Farber Cancer Institute, was featured in a CNN Health report discussing the American Cancer Society’s (ACS) updated prostate cancer screening guidelines saying:

‘Leaving it to each patient and doctor meant a lot of men were simply never offered the test. A clear recommendation fixes that,’

A PSA test is the main screening tool and most common method of screening for prostate cancer. It measures the level of prostate-specific antigen, or PSA, in a sample of your blood.

PSA is a protein produced by the prostate gland, and high levels of PSA in the blood may be caused by cancerous cells in the prostate. But an elevated PSA does not always indicate cancer – it could also be due to an enlarged prostate, common for men as they age, or, less likely, prostate infection.

The new screening guideline describes an abnormal PSA level as being 3 nanograms per milliliter or higher for men 69 and younger, and 6.5 ng/mL or higher for men 70 to 74.

Neeraj Agarwal shared on LinkedIn:

“Grateful to Jacqueline Howard and CNN for the opportunity to discuss American Cancer Society new PSA screening recommendation for Prostate Cancer.

When screening was left to individual discretion, many men were simply never offered the test. A clear recommendation fixes that.

Since 2012, when routine PSA screening was discouraged, we have seen more men present with advanced prostate cancer. Major trials have since shown that screening reduces prostate cancer mortality.

The new guidance:

  • Average risk: PSA every 2 years, ages 50–69
  • Higher risk (including Black men and those with a family history): annual PSA, ages 45–69

If you are a man in these age groups, talk with your doctor about getting screened.”

You can also read:

Neeraj Agarwal: American Cancer Society Updates Its Approach to Prostate Cancer Screening